BioCryst Pharmaceuticals Inc (BCRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
BioCryst Pharmaceuticals Inc stock (BCRX) is currently trading at $9.66. BioCryst Pharmaceuticals Inc PS ratio (Price-to-Sales) is 2.78. Analyst consensus price target for BCRX is $21.20. WallStSmart rates BCRX as Sell.
- BCRX PE ratio analysis and historical PE chart
- BCRX PS ratio (Price-to-Sales) history and trend
- BCRX intrinsic value — DCF, Graham Number, EPV models
- BCRX stock price prediction 2025 2026 2027 2028 2029 2030
- BCRX fair value vs current price
- BCRX insider transactions and insider buying
- Is BCRX undervalued or overvalued?
- BioCryst Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- BCRX Piotroski F-Score and Altman Z-Score
- BCRX analyst price target and Smart Rating
BioCryst Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
BioCryst Pharmaceuticals Inc (BCRX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
BioCryst Pharmaceuticals Inc (BCRX) Key Strengths (2)
Revenue surging 36.10% year-over-year
86.03% of shares held by major funds and institutions
Supporting Valuation Data
BioCryst Pharmaceuticals Inc (BCRX) Areas to Watch (7)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very expensive relative to growth, significant premium
Very expensive at 56.6x book value
Small-cap company with higher risk but more growth potential
Decent operational efficiency, solid but not exceptional
Revenue is fairly priced at 2.78x sales
Supporting Valuation Data
BioCryst Pharmaceuticals Inc (BCRX) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 36.10%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, PEG Ratio. Some valuation metrics including PEG Ratio (9.39), Price/Sales (2.78), Price/Book (56.59) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -1925.00%, Operating Margin at 18.60%, Profit Margin at -1.46%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1925.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 36.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BCRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BCRX's Price-to-Sales ratio of 2.78x trades at a deep discount to its historical average of 78.07x (3th percentile). The current valuation is 99% below its historical high of 444.81x set in Aug 2007, and 18% above its historical low of 2.36x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~2.5x, reflecting growing market expectations outpacing revenue growth.
Compare BCRX with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for BioCryst Pharmaceuticals Inc (BCRX) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
BioCryst Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 600M with 36% growth year-over-year. The company is currently unprofitable, posting a -146.0% profit margin.
Key Findings
Revenue growing at 36% YoY, reaching 600M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 275M in free cash flow and 276M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -146.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can BioCryst Pharmaceuticals Inc maintain 36%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact BioCryst Pharmaceuticals Inc.
Bottom Line
BioCryst Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 36% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -146.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About BioCryst Pharmaceuticals Inc(BCRX)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.